Abivax Shares Drop 4.5% at Midday After a Volatile Sequence
Abivax shares fell 4.54% on Monday, February 2, 2026, at midday, trading at 90.50 euros compared to 94.80 euros last Friday. This correction occurs in a context of high volatility, with the biotech stock having dropped 15.1% over seven days following a spectacular surge of nearly 1,400% over the year.
Analyst Offices Maintain a Positive Outlook Despite Recent Consolidation
Despite the recent consolidation, analyst offices maintain a favorable view on the stock. Stifel raised its price target from 100 to 142 euros in mid-January, accompanied by a buy recommendation, indicating a potential rebound of 57% from the current price. Kepler Cheuvreux also revised its target, increasing it from 70 to 130 euros on January 13, reflecting confidence in the prospects of the laboratory specializing in inflammatory diseases. These evaluations come after a remarkable stock market progression that has propelled the group's market capitalization. The targets set by analysts suggest that the recent decline may be a technical adjustment rather than a fundamental questioning of the growth scenario anticipated by industry professionals.
Technical Analysis Shows Deterioration in Momentum Indicators
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technical analysis reveals a deterioration of momentum indicators. The RSI stands at 35, crossing the threshold of 40 which generally marks a relative oversold zone, indicating a weakening of the bullish momentum of recent weeks. The decline has led to the crossing of several moving averages: the price now moves below its 20-day average (102.22 euros) and its 50-session average (105.13 euros), while it remains well above the 200-day average (59.35 euros). Volatility remains particularly high with a one-month index of 18.91, reflecting the amplitude of recent fluctuations. The resistance is at 122.40 euros, a level that the stock must reconquer to reconnect with its previous upward trajectory.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
